Enveric Biosciences Inc (ENVB) Actualités

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”

Management to meet with investors and potential partners during Biotech Showcase 2025 Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the...

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”

Management to meet with investors and potential partners during Biotech Showcase 2025 Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the...

Form DEF 14A - Other definitive proxy statements

Form PRER14A - Preliminary Proxy Soliciting materials

Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds

New patents provide additional composition of matter and methods of use claims for Enveric’s EVM301 series neuroplastogenic molecules, and...

Form PRE 14A - Other preliminary proxy statements

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior

Dose-proportional oral bioavailability without clinical signs, including those associated with hallucinogenic compounds, was demonstrated in rat...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results

Advanced pre-IND activities and research for lead candidate, EB-003, a novel neuroplastogenic molecule designed to treat severe mental health...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002

Agreement includes development and sales milestones payments potentially totaling up to $62 million as well as tiered single digit royalties on...